Kotsakis, Athanasios

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 182

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Vetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells

Immune cells in cancerAngiogenesis and VEGF in Cancer

Cited by 125

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study

Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 113

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

Georgoulias, V., Androulakis, N., Kotsakis, A., Hatzidaki, D., Syrigos, K., Polyzos, A., Agelidou, A., Varthalitis, I., Ziras, N., Agelidou, M., et al. (2008) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 44

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

Pallis, A. G., Agelaki, S., Agelidou, A., Varthalitis, I., Syrigos, K., Kentepozidis, N., Pavlakou, G., Kotsakis, A., Kontopodis, E., & Georgoulias, V. (2010) · BMC Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 36